Key result
Pembrolizumab yields mixed metastatic tumor responses, with disease progression occurring at 3 months.
Why the study?
Intimal sarcoma is an extremely rare mesenchymal tumor that had not been reported in patients with Lynch syndrome.
Case Report (n=1)
No
This first reported case of pulmonary artery intimal sarcoma in a patient with Lynch syndrome demonstrates that despite MSI-high and TMB-high features, metastatic responses to pembrolizumab can be heterogeneous with rapid development of resistance in liver metastases.
Answers are grounded in this paper and cite their sources.
Heterogeneous responses may limit pembrolizumab durability in metastatic intimal sarcoma; leaves open site-specific resistance mechanisms in MSI-high Lynch-associated tumors.
Intimal sarcoma is an extremely rare mesenchymal tumor arising in the great vessels. To date, intimal sarcoma has not been reported in patients with Lynch syndrome (LS), even though this syndrome lacks DNA mismatch repair ability genetically and is prone to various malignancies. This patient was diagnosed with LS by the Revised Amsterdam Criteria II, and she suffered from intimal sarcoma in the left pulmonary artery. She had a germline missense variant of PMS2 (c.1399G>A, pV467I) which is classified as a variant of unknown significance. In her intimal sarcoma, PMS2 expression was decreased. Additionally, it exhibited microsatellite instability and a high tumor mutational burden (69 mutations/Mb) which are features of mismatch repair deficiency, although PMS2 (c.1399G>A, pV467I) missense is a variant of unknown significance. The metastatic lesions of intimal sarcoma in this patient responded heterogeneously to pembrolizumab, an immune checkpoint inhibitor. Cytotoxic agents and radiation were also effective for some metastatic lesions, but some lesions, including her liver metastases, were resistant. The hypermutable nature of the LS genotype might acquire resistance to an immune checkpoint inhibitor and other cytotoxic agents such as occurred with her liver metastases.
No takes yet. Share an insight, caveat, or question.
Mounai et al. (2023) conducted a case report in Pulmonary artery intimal sarcoma with Lynch syndrome (n=1). Pembrolizumab was evaluated on Tumor response on computed tomography and progression-free survival at 3 months. Pembrolizumab yielded heterogeneous metastatic responses (shrinking lung/pelvic lesions while liver/abdominal wall lesions enlarged), resulting in progressive disease at 3 months and death at 17 months.
Synapse has enriched 10 related papers. Consider them for comparative context: